AzTrials
AzTrials

StrokeAHA-BOOSTNCT06517251

Aha BOOST Arm-hand BOOST Therapy to Enhance Recovery After Stroke: Clinical, Health Economic and Process Evaluation

A study testing Arm-hand BOOST and Lower limb BOOST in people with Stroke, run by KU Leuven at 2 sites in Belgium.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The overall aim of this study is to establish the clinical- and cost-effectiveness of the arm-hand BOOST therapy when delivered on top of the usual care program in the sub-acute phase post stroke and to perform a process evaluation. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Stroke
What is being tested?
Arm-hand BOOST and Lower limb BOOST
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
2 sitesBelgium
Study dates
17 Jun 2024to Dec 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Maximally 5 months after a first-ever unilateral, supra-tentorial stroke
  • Minimally 18 years old
  • A residual inpatient stay of minimally 4 weeks
  • The ability to sit independently
  • Motor impairment in the upper limb, as defined, based on the JSU diagram, as a score of 8-17 on stage 2 (synergies) of the Fugl-Meyer assessment upper extremity (FMA-UE) or a score of <8 on stage 2 of the FMA-UE, combined with a score of >6 on stage 5 (hand) of the FMA-UE.

Who cannot join

  • Severe communication deficits as defined as a score of <24 out of 32 on the 'visual sentence comprehension' subscale of the Comprehensive Aphasia Test.
  • Severe cognitive deficits as defined as a score of <18 out of 30 on the Montreal Cognitive Assessment.

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Geert Verheyden, Professor contact

+32 16 32 91 16

geert.verheyden@kuleuven.be

Belgium2 sites, 2 recruiting
  • Revalidatieziekenhuis RevArte

    Edegem, Antwerpen, 2650

    Recruiting
  • Revalidatiecentrum K7 UZ Gent

    Ghent, Oost-Vlaanderen, 9000

    Not yet recruiting

Other trials in Belgium

About this study

The overall aim of this study is to establish the clinical- and cost-effectiveness of the arm-hand BOOST therapy when delivered on top of the usual care program in the sub-acute phase post stroke and to perform a process evaluation.

In this phase III RCT, 80 patients with stroke will be recruited from two inpatient stroke rehabilitation wards in Belgium and randomized to the experimental group receiving arm-hand BOOST therapy or the control group receiving the L-BOOST intervention, on top of their usual inpatient care program. The arm-hand BOOST program (1 hour/day, 5x/week, 4 weeks) consists of group exercises based on four key aspects, namely neurophysiology, sequences of reaching and grasping, de-weighting of the arm, and orientation of the hand towards objects. Additionally, technology-supported upper limb therapy will be provided two times 30 minutes per week. The L-BOOST intervention comprises a dose-matched program of lower limb exercises and general reconditioning. At baseline, after 4 weeks of training, 3 months after the intervention and at 12 months post stroke, outcome assessment will be performed. The primary outcome measure is the action research arm test (ARAT). Secondary outcomes include measures in the domain of upper limb function and capacity, independence, participation and quality of life. Multivariate ANOVA and sensitivity analyses will be used to compare change from baseline between groups. Information on medical costs will be collected to allow a health economic evaluation. Finally, a process evaluation will be performed to assist in identifying why arm-hand BOOST succeeds or fails unexpectedly or has unanticipated consequences, and how this can be optimized.

At the start of this study the investigators hypothesize that: (I) Aha BOOST will result in a significant greater improvement in arm-hand activity post-intervention, at follow-up and 12 months post stroke compared to control therapy (L-BOOST); (II) Aha BOOST will result in a significant greater improvement in upper limb function, performance, independence and activity of daily living, and participation post-intervention, at follow up and 12 months post stroke. (III) Investing in 24 hours of extra arm-hand therapy to subacute stroke patient in the inpatient rehabilitation setting can reduce the health-economic and societal cost 12 months post stroke.

Read the detailed description

Data collection and transfer:

  • Data will be collected by the clinical sites and by the external researchers from the KU Leuven, VUB and Jessa Hospital. Source documents will be used to collect the data, these can be on paper or digital document.
  • Different kinds of data will be collected on paper, for example results of the clinical tests, questionnaires and diaries. A standardized case report form (CRF) will be completed during data collection, containing researchers notes, remarks concerning data quality, contextual information, deviations from the protocol, etc. These CRFs will be kept on paper, in the same folder as the research data that are collected on paper and will become part of the participant's source documentation. These forms will be digitalized by the researchers in the e-CRFs via REDCap. After digitalizing the data, these paper forms will be stored in a locked cabinet in the Department of Rehabilitation Sciences, Building The Nayer, of the KU Leuven. During data collection temporary storage is possible at building K on the health campus in Jette, of the VUB. Only authorized personnel will have access to this locked storage rooms as they will need to be granted access by the PI.
  • The data collected by the clinical sites will consists of a combination of paper forms and digital documents. A ManGO platform (hosted by KU Leuven IT department) will be used for collecting these different pseudonymized data forms. The different paper forms and data received via ManGO will be processed to REDCap by the external researchers. After digitalizing the data, the paper forms will be stored in a locked cabinet in the Department of Rehabilitation Sciences, Building The Nayer, of the KU Leuven. During data collection temporary storage is possible at building K on the health campus in Jette, of the VUB. Only authorized personnel will have access to this locked storage rooms as they will need to be granted access by the PI. The recorded video's will be transferred via ZIVVER, after which they will processed by the external researchers and deleted both on the computer of the external researcher and in the clinical sites.
  • Any participant records or datasets that are transferred to the Sponsor or any partners of the Sponsor will contain the study-specific participant identifier only; participant names or any information which would make the participant identifiable will not be transferred. All pseudonymized data relating to the Investigation must be transmitted in a secure manner to the Sponsor or any partners of the Sponsor via the ManGO platform or Zivver. Interim reports and a final report at the group level (without individual patient data) will be provided to the funder (FWO).

Power calculation:

  • A power calculation was done based on the primary research question (evaluating the short-term clinical effect of Aha BOOST intervention versus the control intervention on arm-hand capacity). This give the following results: In the proof of concept RCT, an average difference of 7.8 points in ARAT between both groups, in change from pre- to post intervention was found. Furthermore, the standard deviation of change from pre- to post intervention was estimated to be 11.7 points for the ARAT scale. With 74 patients, the comparison between experimental and control group for change from pre- to post intervention will have 80% power to detect an average difference of at least 7.8 points at the 5% two-sided level of significance, assuming a standard deviation of at most 11.7 points.
  • To account for an expected dropout of at most 8%, 80 patients will be recruited.

Statistical analysis:

  1. Clinical data: Changes in ARAT-scores from baseline between patients in the experimental and control group will be compared. Change from baseline will be estimated in both groups based on a multivariate ANOVA model for the original ARAT scores, with time and treatment as main effects and with time by treatment interaction. As a further sensitivity analysis, the analysis will be repeated correcting for patient characteristics such as age, time post stroke, and cognitive impairments. Secondary outcome measures: Multivariate ANOVA and sensitivity analyses, as described above. Subgroup analyses: pre-specified subgroup analyses will be undertaken to explore the effects of the interventions in different types of stroke survivors, such as experiencing cognitive impairments, using appropriate caution about multiplicity in the interpretation of these results. If there appear to be different effects in different subgroups, this will be investigated using interaction or trend tests rather than the statistical significance of the result for the individual subgroup.
  2. Health economic data: The economic evaluation will incorporate costs and health gains during the trial and follow-up period, adopting healthcare and societal perspectives. On the cost side, the evaluation will focus on the direct medical and non-medical costs, and on indirect costs depending on the perspective. The direct medical costs encompass all costs for treatment and follow-up from the healthcare perspective and all out-of-pocket contributions by the participant. Direct non-medical costs include transport costs, and home care help, whereas indirect costs include productivity loss (e.g. the number of days away from work). Productivity losses due to informal care will be documented and valued using the human capital approach. The effects are expressed in utilities, derived from the national values of the EQ-5D-5L. The cost-effectiveness of the intervention will be expressed in incremental cost per QALY (quality-adjusted life years), using a decision-analytic model based on the trial data with a time horizon of one year and on a lifetime horizon. The incremental cost per QALY will be calculated as a ratio of (Cost Experimental-Cost Control) / (Outcome Experimental-Outcome Control). The robustness of the results will be analyzed by probabilistic sensitivity analyses on the cost as well as on the outcome. Tornadodiagrams will be used to measure impact of individual components in healthcare utilization. Probabilistic sensitivity analyses by bootstrapping with replacement will be employed to test the robustness of the results, utilizing MS Excel, using a minimum of 1000 iterations to obtain 2.5% and 97.5% percentiles of the incremental cost-effectiveness ratio (ICER) distribution. In a second phase, the health economic model will be further extended from a one-year time horizon to a life-time horizon based on literature. A Markov-model is developed defining the health states in chronic stroke. Estimations on resource use and utilities for each health state are derived from international peer-reviewed literature. Special attention is paid to the transferability of the data to the Flemish healthcare context. This will done by validation checks within the research consortium and advisory board. Similar to the one-year model, probabilistic sensitivity analyses will be used to account for uncertainty around the input parameters
  3. Process evaluation data: Qualitative data will be analyzed using content analysis (a deductive analysis based on the defined indicators) and thematic analysis (an inductive analysis where themes will be generated from the data by the researcher(s) using a generic qualitative approach). The aim is to interview +/- 16 interviewees to achieve meaning saturation per respondent group (patients, expert therapists and treating physicians). Approximately 48 interviews will be conducted, although the final numbers will be determined by saturation. Interviews will be audio recorded, transcribed at verbatim and analyzed in NVIVO. Different types of data-triangulation, by using different methods or data-sources to gain a more in depth understanding, will be applied: (1) methodological triangulation e.g. using a combination of interviews and observations; (2) data triangulation e.g. patients, Aha BOOST therapists and treating physicians; (3) theoretical triangulation e.g. involving researchers of different disciplines to look to the data from different perspectives; (4) investigator triangulation e.g. involving different researchers in data analysis.
Conditions
Stroke
Being tested
Arm-hand BOOST, Lower limb BOOST
Keywords
Randomized controlled trial, Upper extremity, Subacute stroke, Inpatient rehabilitation, Additional therapy, Clinical evaluation, Health-economic evaluation, Process evaluation
Medical subject headings
Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Arm-hand BOOSTOther

    Also called Aha BOOST

    Aha BOOST consists of 20 one-hour BOOST sessions (spread over 4 weeks, 5 days a week) and one hour of individual technology-supported therapy per week (divided in two times 30 minutes), with the aim to provide intensive, goal-oriented upper limb therapy. The sessions will be executed with a maximum of two participants, under supervision of a trained therapist.

    The group sessions are focused on four key aspects: neurophysiology, sequences of reaching and grasping, de-weighting of the arm, and orientation of the hand towards objects. The different exercises are tailored to the individual patient, based upon ongoing assessment, discussion within the group of therapists, and individual treatment goals of the patient. Additionally, patients exercise two times 30 minutes per week with the AMADEO® (Tyromotion, Austria), an upper limb robotic device, focusing on finger and hand rehabilitation.

  • Lower limb BOOSTOther

    Also called L-BOOST

    L-BOOST consists of 20 one-hour sessions and a personalized two times 30 minutes self-exercise program per week and focused on strengthening exercises for the lower limbs and general reconditioning. During the group sessions, circuit-class training is performed according to a standardized written protocol: 20 minutes of cycling on a sitting bike, 20 minutes of strengthening exercises for muscles around hip and knee (e.g. sit-to-stand training), 10 minutes of knee exercises using quadriceps bench in free swing mode and 10 minutes of leg press exercises. Again, a gradual increase in levels of difficulty is provided. Additionally, each patient receives a self-exercise program (balance; strengthening of foot, knee, and hip muscles; walking exercises), which is executed two times 30 minutes per week under minimal supervision of a therapist. None of the exercises involve the use of the upper limb.

Study groups in NCT06517251
Study groupRoleWhat they receive
Arm-hand BOOST (Aha BOOST)ExperimentalAha BOOST consist of 20 one-hour group sessions (spread over 4 weeks, 5 days a week) and one hour of individual therapy per week (divided in two times 30 minutes). This group will receive therapy for the upper extremity.
Receives: Other: Arm-hand BOOST
Lower limb BOOST (L-BOOST)Active comparatorL-BOOST consist of 20 one-hour group sessions (spread over 4 weeks, 5 days a week) and one hour of individual therapy per week (divided in two times 30 minutes). This group will receive therapy for strengthening exercises the lower limbs and general reconditioning.
Receives: Other: Lower limb BOOST

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Action Research Arm Test (ARAT)

    The Action Research Arm Test (ARAT) is the recommended outcome in stroke trials, measuring arm-hand capacity at ICF activity level.

    The total score ranges from 0 to 57, with higher scores representing better performance.

    Measured: Pre-intervention, immediate post-intervention (after 4 weeks of additional therapy), 3 months post-intervention and 12 months post-stroke.

Secondary outcomes (6)
  1. Fugl-Meyer assessment- upper extremity (FMA-UE)

    Assessing the domain of upper limb function. The total score ranges from 0-66, where 0 indicates no motor function and 66 indicates intact motor function.

    Measured: Pre-intervention, immediate post-intervention (after 4 weeks of additional therapy), 3 months post-intervention and 12 months post-stroke.

  2. Stroke Upper Limb Capacity Scale (SULCS)

    Assessing the domain of upper limb capacity. The total score ranges from 0-10 and reflects the number of items a person can execute.

    Measured: Pre-intervention, immediate post-intervention (after 4 weeks of additional therapy), 3 months post-intervention and 12 months post-stroke.

  3. Barthel Index (BI)

    Assessing the domain of independence. The total score ranges from 0 (indicating total dependence) to 100 (indicating complete independence).

    Measured: Pre-intervention, immediate post-intervention (after 4 weeks of additional therapy), 3 months post-intervention and 12 months post-stroke.

  4. modified Rankin Scale (mRS)

    Assessing the domain of independence. mRS is a 7-point ordinal scale ranging from 0(no symptoms) to 6 (death).

    Measured: Pre-intervention, immediate post-intervention (after 4 weeks of additional therapy), 3 months post-intervention and 12 months post-stroke.

  5. Stroke Impact Scale (SIS)

    Assessing the domain of participation. For each subcategory, a domain score is calculated, ranging from 0 to 100, with higher scores indicating less impact.

    Measured: Pre-intervention, immediate post-intervention (after 4 weeks of additional therapy), 3 months post-intervention and 12 months post-stroke.

  6. EuroQOL (EQ-5D-5L)

    Assessing the domain of quality of life. This test compromises five dimensions, each scored on a 5-level scale: no problems, slight problems, moderate problems, severe problems, unable to/extreme problems.

    Measured: Pre-intervention, immediate post-intervention (after 4 weeks of additional therapy), 3 months post-intervention and 12 months post-stroke.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jul 2024
  2. Study start17 Jun 2024
  3. Primary completionDec 2027 (estimated)
  4. Study completionDec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Assessor-blinded phase III randomized controlled trial with a parallel design
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06517251
Sponsor's protocol ID
S68329
Other IDs
T002323N
Acronym
AHA-BOOST
Status last verified
Mar 2026
First submitted
3 Jul 2024
Last updated
19 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data will be available in a restricted access repository. The full pseudonymized dataset will be made available as open as possible, as closed as necessary after publication of the data. This because of the type of data (sensitive and personal). All the data will be made available for other research purposes regarding the same pathology (stroke) of the consortium partners (KU Leuven, VUB and Jessa), this after approval of an ethical committee. Additionally, the dataset could be made available for other doctors and institutions collaborating with the consortium partners after submitted a written request to the PI, approval of an ethical committee and based on a Data Transfer Agreement (DTA).

Publications

  • Cornelis L, Cruycke L, Meyer S, De Smedt A, Fobelets M, Michielsen M, Vander Plaetse M, Putman K, Verheyden G. Additional arm-hand boost therapy (AHA-BOOST) in an inpatient rehabilitation setting during the subacute phase after stroke: protocol for a randomised controlled trial including a clinical, process and health economic evaluation. BMJ Open. 2025 Oct 10;15(10):e093079. doi: 10.1136/bmjopen-2024-093079.

    PubMed 41073121

Questions about this trial

What is this clinical trial studying?

A study testing Arm-hand BOOST and Lower limb BOOST in people with Stroke, run by KU Leuven at 2 sites in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 19 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Geert Verheyden, Professor (+32 16 32 91 16, geert.verheyden@kuleuven.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Action Research Arm Test (ARAT) (time frame: Pre-intervention, immediate post-intervention (after 4 weeks of additional therapy), 3 months post-intervention and 12 months post-stroke.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06517251, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in